

*National Imaging Associates, Inc.*	
Clinical guideline TRANSTHORACIC (TTE) ECHO	Original Date: October 2009
CPT codes: 93303, 93304, 93306, 93307, 93308, +93320, +93321, +93325, +93356	Last Revised Date: <del>April February</del> 20 <del>23</del> <del>22</del>
Guideline Number: NIA_CG_067	Implementation Date: January 202 <del>4</del> <del>3</del>

### GENERAL INFORMATION

- *It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.*
- *Where a specific clinical indication is not directly addressed in this guideline, medical necessity determination will be made based on widely accepted standard of care criteria. These criteria are supported by evidence-based or peer-reviewed sources such as medical literature, societal guidelines and state/national recommendations.*

### GENERAL INFORMATION

~~It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.~~

### ADULT PATIENTS – INDICATIONS FOR TRANSTHORACIC ECHOCARDIOGRAPHY (TTE)<sup>1</sup>

(Indications for [pediatric patients](#) follow this section)

#### Evaluation of Cardiac Structure and Function

- When initial evaluation including history, physical examination, electrocardiogram (ECG), remote monitor or other testing suggests a cardiac etiology for symptoms, including but not limited to:
  - Chest pain when another study is not planned to evaluate

\*National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.

- Shortness of breath
- Palpitations
- Hypotension suggestive of cardiac etiology not due to other causes, such as:
  - Medications, dehydration, or infection
- ECG Abnormalities
  - Previously unevaluated pathological Q waves (in two contiguous leads) defined as the following:
    - > 40 ms (1 mm) wide
    - > 2 mm deep
    - > 25% of depth of QRS complex
  - New left bundle branch block (as documented in MD notes and on ECG).
    - New isolated RBBB is **not** an indication for TTE.
  - Previously unevaluated left ventricular hypertrophy (i.e., concern for hypertrophic cardiomyopathy).

## Murmur or Click

- Initial evaluation when there is a reasonable suspicion for valvular or structural heart disease such as:
  - High grade  $\geq 3/6$ : Note that TTE can be approved for documented concern that murmur suggests a **specific valve pathology** (such as “aortic valve sclerosis/stenosis” or “mitral regurgitation”) **regardless of grade of murmur**
  - Holosystolic
  - Continuous
  - Diastolic

## Arrhythmias

- Frequent premature ventricular contractions (PVCs, greater than 30 per hour on remote monitoring or  $\geq 1$  PVC on 12 lead ECG)
  - Isolated premature atrial complexes (PACs) are not an indication for TTE.
- Sustained or nonsustained ventricular tachycardia (VT) or ventricular fibrillation (VF), or ventricular bigeminy
- New onset atrial fibrillation (as documented in MD notes and on ECG) which was not evaluated by a prior transthoracic echocardiogram (TTE)

~~New left bundle branch block (as documented in MD notes and on ECG)~~

## Syncope<sup>2, 3</sup>

- History, physical examination, or electrocardiogram (ECG) consistent with a cardiac diagnosis known to cause presyncope or syncope, including but not limited to, known or suspected:
  - Structural heart disease (including but limited to):
    - Hypertrophic cardiomyopathy
    - Systolic heart failure
  - ~~Heart failure~~
  - ~~Myocardial dysfunction~~
  - Exercise-induced syncope
  - ~~Valvular heart disease~~
  - ~~Coronary artery disease~~
- And not due to other causes such as:
  - ~~Vaso-vagal syncope,~~
  - ~~n~~ Neurogenic orthostatic syncope
  - Orthostasis related to medication or dehydration

## Perioperative Evaluation<sup>4, 5</sup>

- Preoperative left ventricular function assessment in patients who are candidates for solid organ transplantation (can be done yearly prior to transplant)

## Pulmonary Hypertension

- Evaluation of suspected pulmonary hypertension including evaluation of right ventricular function and estimated pulmonary artery pressure
- Re-evaluation of known pulmonary hypertension if there is a change in clinical status or cardiac exam or a need to change medications<sup>6</sup> ~~(can be done every 6-12 months),~~<sup>6</sup> such as:
  - New chest pain
  - Worsening shortness of breath
  - Syncope
  - Increased murmur
  - Worsening rales on lung examination
- Initial ~~E~~evaluation of patients with pulmonary embolism to risk stratify and initiate appropriate therapy<sup>7</sup>
  - Repeat TTE can be approved for persistent dyspnea 3-6 months after PE<sup>8</sup> to evaluate for possible chronic thromboembolic pulmonary hypertension (CTEPH)
- ~~Screening test for pulmonary hypertension in patients with scleroderma or sickle cell anemia~~

- Annual surveillance-screening (i.e., initial screening TTE is negative) can be performed annually for pulmonary hypertension in patients with<sup>6, 9</sup>:
  - Scleroderma
  - Portal hypertension (including evaluation prior to TIPS procedure)
  - Carriers of Bone Morphogenic Protein Receptor 2 (BMPR2) mutation
  - Sickle cell disease

### **Evaluation of Valvular Function<sup>2, 10-12</sup>**

- Screening of first-degree relatives of patients with a bicuspid aortic valve

### **Native Valvular Stenosis**

- Routine surveillance ( $\geq 3$  yrs.) of bicuspid aortic valve, aortic sclerosis, or mild valvular stenosis
- Re-evaluation ( $\geq 1$  yr) of moderate stenosis
- Re-evaluation of severe aortic stenosis (AS) every 6 - 12 months
- Re-evaluation after starting medication in patients with low flow/low gradient severe aortic stenosis

### **Native Valvular Regurgitation<sup>2, 13, 14</sup>**

- Re-evaluation ( $\geq 3$  yrs.) of mild valvular regurgitation
- Re-evaluation ( $\geq 1$  yr) of moderate valvular regurgitation
- Re-evaluation of asymptomatic patient every 6 - 12 months with severe valvular regurgitation

### **Prosthetic Valves/Native Valve Repair**

- Initial evaluation of prosthetic valve or native valve repair, for establishment of baseline, typically 6 weeks to 3 months postoperative
- Routine surveillance of surgical bioprosthetic valve: every 3 years after surgery
- Routine surveillance of surgical bioprosthetic and mechanical valve: at 10 years postoperatively and annually thereafter
- Routine surveillance of surgical mitral valve repair: 1-year- post-op and then every 2-3 years
- Evaluation of prosthetic valve or native valve repair with suspected dysfunction, with symptoms including but not limited to:
  - Chest pain
  - Shortness of breath
  - New or Increased murmur on heart examination
  - New rales on lung examination
  - Elevated jugular venous pressure on exam

## Transcatheter Heart Interventions

### Transcatheter Aortic Valve Replacement (TAVR)<sup>2, 12, 15</sup>

- Pre TAVR evaluation
- Post TAVR at 30 days (6 weeks to 3 months also acceptable) and annually
- Assessment post TAVR when there is suspicion of valvular dysfunction, including but not limited to:
  - Chest pain
  - Shortness of breath
  - New or increased murmur on heart examination
- Assessment of stroke post TAVR

### Percutaneous Mitral Valve Repair<sup>2, 12, 13</sup>

- Pre-procedure evaluation
- Reassessment for degree of MR and left ventricular function (1, 6 months, and annually)

### Closure of PFO or ASD<sup>10</sup>

- Pre-procedure evaluation
- Routine follow-up post procedure for device position and integrity (see [Table 2: Adult and Pediatric Congenital Heart Disease Follow-Up](#))
- Evaluation for clinical concern for infection, malposition, embolization, or persistent shunt
- Routine surveillance of an asymptomatic patient with a PFO is **not** indicated<sup>16</sup>

### Left Atrial Appendage (LAA) Occlusion<sup>10</sup>

- Pre-procedure evaluation

### Pericardial Disease<sup>7, 10, 17, 18</sup>

- Suspected pericardial effusion
- Re-evaluation of known pericardial effusion when findings would lead to change in management
- Suspected pericardial constriction or reevaluation of status when management would be changed

### Evaluation of Cardiac Source of Emboli or Cardiac Mass<sup>2</sup>

- Embolic source in patients with recent transient ischemic attack (TIA), stroke, or peripheral vascular emboli
- Evaluation of intracardiac mass or re-evaluation of known mass<sup>19</sup>

## Infective Endocarditis (Native or Prosthetic Valves)<sup>2, 11, 20, 2, 11, 20</sup>

- Initial evaluation of suspected infective endocarditis with positive blood cultures or a new murmur
- Re-evaluation of infective endocarditis with, but not limited to:
  - Changing cardiac murmur
  - Evidence of embolic phenomena such as TIA or CVA
  - New chest pain, shortness of breath, or syncope
  - A need to change medications due to ongoing fever, positive blood cultures, or evidence of new AV block on ECG
- Re-evaluation of patient with infective endocarditis at high risk of progression or complication (extensive infective tissue/large vegetation, or staphylococcal, enterococcal, or fungal infections)
- At completion of antimicrobial therapy and serial examinations at 1, 3, 6, and 12 months during the subsequent year<sup>20</sup>

## Thoracic Aortic Disease<sup>21-26</sup>

In the absence of recent computed tomography (CT) or cardiovascular magnetic resonance (CMR), which are preferred for imaging beyond the proximal ascending aorta

- Screening of first-degree relatives of individuals with:
  - Thoracic aortic aneurysm (defined as  $\geq 50\%$  above normal) or dissection,
  - Bicuspid aortic valve
  - or if an associated high-risk mutation is present Presence of an aortopathic syndrome (i.e., Marfan's, Ehlers-Danlos, Loeys-Dietz, or Turner's)
- If one or more first-degree relatives of a patient with a known thoracic aortic aneurysm or dissection, have thoracic aortic dilatation, aneurysm, or dissection; then imaging of 2<sup>nd</sup> degree relatives is reasonable
- Six-month follow-up after initial finding of a dilated thoracic aorta
- Annual follow-up of enlarged thoracic aorta that is above top normal for age, gender, and body surface area
- Biannual (twice/year) follow-up of enlarged aortic root  $\geq 4.5$  cm or showing growth rate  $\geq 0.5$  cm/year
- Evaluation of the ascending aorta in known or suspected connective tissue disease or genetic conditions that predispose to aortic aneurysm or dissection (e.g., Marfan syndrome, Ehlers-Danlos or Loeys-Dietz syndromes) at time of diagnosis and 6 months thereafter for growth rate assessment, followed by annual imaging, or biannual (twice yearly) if diameter  $\geq 4.5$  or expanding  $\geq 0.5$  cm/yr
- ~~Patients with Turner's syndrome should undergo imaging to assess bicuspid aortic valve, coarctation of the aorta or dilation of the ascending or thoracic aorta. If the initial~~

~~imaging is normal and there are no additional risk factors for dissection, imaging can be done every 5–10 years. If an abnormality exists, annual imaging is recommended~~

- Turner's Syndrome:
  - Baseline evaluation at the time of diagnosis to assess for bicuspid aortic valve, coarctation of the aorta, aortic root and ascending aortic dilatation and other congenital defects.
  - Surveillance imaging (initial imaging normal and no additional risk factors for dissection such as HTN or bicuspid aortic valve):
    - Children: every 5 years
    - Adults: every 10 years
    - Prior to planned pregnancy
    - Annual imaging can be approved if an abnormality is found<sup>27</sup> (such as bicuspid aortic valve)
- Re-evaluation of known ascending aortic dilation or history of aortic dissection with one of the following:
  - New chest pain
  - Shortness of breath
  - Syncope
  - TIA or CVA
  - New or increased aortic valve murmur on clinical examination
  - New rales on lung examination or increased jugular venous pressure
  - **OR** when findings would lead to referral to a procedure or surgery
- ~~Re-evaluation (< 1 yr, generally twice a year) of the size and morphology of the aortic sinuses and ascending aorta in patients with a bicuspid aortic valve with one of the following:~~
  - ~~Aortic diameter  $\geq$  4.5 cm~~
  - ~~Rapid rate of change in aortic diameter when an annual growth rate of  $\geq$  0.5 cm is suspected~~
  - ~~Family history (first-degree relative) of aortic dissection~~
- Follow-up of aortic disease when there has been no surgical intervention:
  - Acute dissection: 1 month, 6 months, 12 months, then annually
  - Chronic dissection: annually
- ~~Follow-up post either: Root repair or AVR plus ascending aortic root/arch repair:~~
- ~~— baseline post-op, then annually<sup>21</sup>~~ thoracic aortic aneurysm repair: chest CTA or chest MRA are the recommended surveillance imaging modalities.
- ~~Evaluation of sinus of Valsalva aneurysms and associated shunting secondary to rupture.<sup>25</sup> Echo imaging every 4–12 weeks is recommended during pregnancy and 6 months post-partum in patients with ascending aortic dilation~~ Evaluation of sinus of Valsalva aneurysms and associated shunting secondary to rupture.<sup>20</sup> Echo imaging every 4–12 weeks is recommended during pregnancy and 6 months post-partum in patients with ascending aortic dilation<sup>24</sup>
-

## Hypertension (HTN) (Adult)<sup>10, 27</sup>

- Initial evaluation of suspected hypertensive heart disease including but not limited to the following:
  - Left ventricular hypertrophy on ECG
  - Cardiomegaly
  - Evidence of clinical heart failure

## Hypertension (HTN) (Pediatric)<sup>28</sup>

- Initial evaluation at time of consideration of pharmacologic treatment of HTN
- Re-evaluation at 6–12-month intervals for:
  - Persistent HTN despite treatment
  - Concentric LVH on prior study
  - Reduced LVEF on prior study
- Re-evaluation of patients without LVH on initial evaluation can have TTE annually for:
  - Stage 2 HTN (BP  $\geq$ 140/90 mm Hg)
  - Secondary HTN
  - Chronic stage 1 HTN (BP between [130/80- and 139/89-mm](#) Hg) incompletely treated, including drug resistance and noncompliance

## Heart Failure<sup>10, 29-31</sup>

- Initial evaluation of suspected heart failure (HF) (systolic or diastolic) based on symptoms, signs, or abnormal test result, including but not limited to:
  - Dyspnea
  - Orthopnea
  - Paroxysmal nocturnal dyspnea
  - Worsening edema
  - Elevated BNP
- Re-evaluation of known HF (systolic or diastolic) with a change in clinical status or cardiac exam (as listed above)

## Cardiomyopathy<sup>10, 30-34</sup>

- Initial evaluation of suspected inherited or acquired cardiomyopathy, including but not limited to:
  - Restrictive
  - [Infiltrative/Depositional \(i.e., hemochromatosis/iron overload, mucopolysaccharidoses, mitochondrial or metabolic storage disease \(e.g., Danone disease, Fabry disease\)\)](#)
    - [Fabry disease: annual surveillance TTE may be approved for patients receiving enzyme replacement](#)<sup>19</sup>



- Dilated
- Hypertrophic
- ~~R~~Infective Re-evaluation of known cardiomyopathy if there is a need to monitor a change in medications or new symptoms, including but not limited to:
  - Chest pain
  - Shortness of breath
  - Palpitations
  - Syncope
- Heart failure (including Takotsubo cardiomyopathy)<sup>19</sup> with recovered left ventricular ejection fraction defined as (must meet all 3 criteria):
  - Documentation of a decreased LVEF <40% at baseline
  - ≥10% absolute improvement in LVEF
  - A second measurement of LVEF >40%<sup>35</sup>:
    - Repeat echocardiogram every 6 months until 12-18 months after recovery of EF, then annually for 2 years, then every 3-5 years
    - Higher risk patient (persistent left bundle branch block, genetic cardiomyopathy, higher biomarker profiles) may have annual follow-up
- Screening evaluation in first-degree relatives of a patient with an inherited cardiomyopathy
- Suspected cardiac sarcoidosis, including as a screening study in patients with biopsy proven extracardiac sarcoidosis<sup>36</sup>
- Suspected cardiac amyloid and to monitor disease progression and/or response to therapy, and to guide initiation and management of anticoagulation (TEE may be preferred)<sup>34, 39</sup>
  - Light chain amyloidosis (AL): TTE may be repeated every 3-6 months
  - Transthyretin amyloidosis (ATTR): TTE may be repeated every 6-12 months<sup>19</sup>

### Hypertrophic Cardiomyopathy (HCM)<sup>33</sup>

- Initial evaluation of suspected HCM
- Re-evaluation of patients with HCM with a change in clinical status or a new clinical event
- Evaluation of the result of surgical myomectomy or alcohol septal ablation
- Re-evaluation in patients with no change in clinical status or events every 1 - 2 years to assess degree of myocardial hypertrophy, dynamic obstruction, MR, and myocardial function
- Evaluation of patients with HCM who have undergone septal reduction therapy within 3-6 months after the procedure
  - Screening for patients who are clinically unaffected or (genotype-positive and phenotype-negative):
    - Children and adolescents, every 1-2 years

- Adults every 3-5 years
- Screening of first-degree relatives is recommended at the time HCM is diagnosed in the family member and serial follow-up as below:
  - Children and adolescents from genotype-positive families and families with early onset disease every 1-2 years
  - All other children and adolescents every 2-3 years
  - Adults every 3-5 years
- To guide therapy
  - Camzyos (mevacamten): baseline TTE prior to initiation. Repeat TTE during therapy at the discretion of the ordering physician<sup>37</sup>.

### Imaging Surveillance for Cardiotoxic ~~Chemotherapy~~Medication<sup>38, 39</sup>

- TTE is the method of choice for the evaluation of patients who will receive or have received prior to cardiotoxic ~~chemotherapy~~ medication.; TTE may be approved for:
  - Baseline assessment prior to initiation of therapy
  - Monitoring during therapy ~~and subsequently for monitoring and follow-up~~. The frequency of testing should be left to the discretion of the ordering physician, but in the absence of new abnormal findings, generally no more often than ~~at baseline and~~ every 6 weeks ~~thereafter~~ while on active therapy.
  - Long term surveillance after completion of therapy may be required, especially for those who have been exposed to anthracycline medication. The frequency of testing is generally every 6-12 months, or at the discretion of the provider.

### Imaging Surveillance for Previous Radiation Therapy with Cardiac Exposure<sup>40</sup>

- TTE is indicated for long term surveillance, generally at 5 years and at 10 years following radiation exposure. More frequent surveillance may be indicated at the discretion of the provider.

### Device Candidacy or Optimization (Pacemaker, ICD, or CRT)

- Initial evaluation or re-evaluation after revascularization ( $\geq 90$  days) and/or myocardial infarction ( $\geq 40$  days) and/or 3 months of guideline-directed medical therapy when ICD is planned<sup>41,33</sup>
- Initial evaluation for CRT device optimization after implantation
- Re-evaluation for CRT device optimization in a patient with worsening heart failure
- Known implanted pacing device with symptoms possibly due to device complication or suboptimal pacing device settings

### Ventricular Assist Devices (VADs) and Cardiac Transplantation<sup>10, 42</sup>

- To determine candidacy for VAD

- Optimization of VAD settings and assessment of response post device
- Re-evaluation for signs/symptoms suggestive of VAD-related complications, including but not limited to:
  - TIA or stroke
  - Infection
  - Murmur suggestive of aortic insufficiency
  - Worsening heart failure

### **Post Heart Transplant Surveillance Imaging**

- Monitoring ~~annually~~ every 6 months (or at the discretion of the transplant center) for rejection in a cardiac transplant recipient. May be approved for more frequent monitoring in the first-year post-transplant<sup>43</sup>.

### **Cardiovascular Disease in Pregnancy<sup>32, 44</sup>**

- Valvular stenosis
  - Mild can be evaluated each trimester and prior to delivery
  - Moderate-severe can be evaluated monthly
- Valvular regurgitation
  - Mild-moderate regurgitation can be evaluated each trimester and prior to delivery
  - Severe regurgitation can be evaluated monthly
- Pre-pregnancy evaluation with mechanical or bioprosthetic heart valves (if not done within the previous year)
- Prior Postpartum Cardiomyopathy: can be repeated at the end of the 1st and 2nd trimesters, 1 month prior to delivery, after delivery prior to hospital discharge, 1 month postpartum, and serially including up to 6 months after normalization of ejection fraction
- ~~Aortopathic S~~syndromes potentially involving the aorta (i.e., Marfan's, Ehlers-Danlos, Loeys-Dietz, or Turner's ~~syndrome~~) or known dilated aortic root or ascending aorta: may be approved for pre-pregnancy planning and for monitoring each trimester during pregnancy and again several weeks post-partum. More frequent imaging may be approved depending on aortic diameter, aortic growth rate and comorbidities predisposing to dissection (i.e., presence of an aortopathic syndrome, HTN)<sup>27</sup>. ~~for mildly dilated aorta can repeat TTE every 12 weeks (about 3 months); for severely dilated aorta can repeat TTE monthly; can evaluate for 6 months postpartum~~
- 

### **Adult Congenital Heart Disease<sup>16, 45, 46</sup>**

- Initial evaluation of suspected adult congenital heart disease

- Known adult congenital heart disease with a change in clinical status or cardiac exam, including but not limited to:
  - Chest Pain
  - Shortness of breath
  - New or increased murmur on physical exam
- Evaluation prior to surgical or transcatheter procedure
- For follow-up of specific lesions, see [Table 1](#) and [Table 2](#): **Adult and Pediatric Congenital Heart Disease Follow-up**

### **Inflammatory & Autoimmune**

- Including any one of the following:
  - Suspected rheumatic fever<sup>47</sup>
  - Systemic lupus erythematosus<sup>48</sup>
  - Takayasu arteritis<sup>49</sup>
  - Multisystem Inflammatory Syndrome (MIS): at baseline and for surveillance when there is documented concern for coronary involvement or other late sequelae<sup>50</sup>
  - Kawasaki disease<sup>51</sup>
    - Upon diagnosis, 1-2 weeks later, and 4 to 6 weeks after diagnosis
    - For patients with important and evolving coronary artery abnormalities during the —acute illness, echocardiograms may need to be more frequent. In the setting of increasing size of coronary aneurysms, echocardiogram can be performed up to twice per week until dimensions have stopped progressing, then at least once per week in the first 45 days of illness, and then monthly until the third month after onset.
    - For persistent coronary aneurysm after the acute illness, echocardiogram surveillance intervals are based on the size of the aneurysm:
      - Small: at 6 months. and then yearly
      - Medium: at 3, 6 and 12 months and then every 6-12 months
      - Large/Giant: at 3, 6, 9 and 12 months and then every 3-6 months

### **COVID-19**<sup>52</sup>

- Acute infection
  - Cardiopulmonary signs or symptoms (ECG abnormalities, elevated biomarkers, chest pain, dyspnea, syncope, palpitations)
- Post-Acute Sequelae (PASC) defined as new or returning cardiopulmonary symptoms 4 or more weeks and persisting more than 2 months following confirmed COVID infection, not explained by an alternative diagnosis (WHO definition).

- Post Vaccination
  - Symptoms or signs of myocarditis (ECG abnormalities, chest pain, elevated biomarkers)

### **Surveillance for Neuromuscular Disorders**<sup>53</sup>

Asymptomatic surveillance intervals (genetically affected individuals with no signs or symptoms of cardiac involvement). Development of signs or symptoms of cardiac involvement necessitates more frequent assessment.

~~Development of signs or symptoms necessitates more frequent assessment~~

- Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD)
  - age <10 years, TTE every 2 years
  - age 10 years or older, TTE annually
  - CMR can be performed if TTE is technically difficult
- Emery-Dreifuss muscular dystrophy (EDMD)
  - X-linked form: at least annual TTE
  - Autosomal form: TTE at initial diagnosis, surveillance TTE only if initial TTE abnormal
- Myofibrillar myopathy (MFM)
  - Annual TTE
- Barth (BTHS)-X linked recessive (only males develop disease)
  - Infant males TTE every 6 months
  - Age 1 year or older, annual TTE
- Limb-Girdle muscular dystrophy (LGMD)
  - TTE may be performed annually
- Friedrich's ataxia (FA)
  - TTE can be performed at least yearly annually
- Myotonic dystrophy (DM)
  - TTE every 2-4 years

### **PEDIATRIC PATIENTS - INDICATIONS FOR TRANSTHORACIC ECHOCARDIOGRAPHY (TTE) (PATIENTS UNDER THE AGE OF 18)<sup>54,39</sup>**

- Hypertension (see section: [Hypertension \(Pediatric\)](#))
- Renal failure
- Palpitations, if one:
  - Family history at age < 50 of either:
    - Sudden cardiac death/arrest **OR**
    - Pacemaker or ICD
  - History or family history of cardiomyopathy
- Chest pain, if one or more of the following:

- Exertional chest pain
- Abnormal ECG
- Family history with unexplained sudden death or cardiomyopathy
- Syncope, if any of the following:
  - Abnormal ECG
  - Exertional syncope
  - Family history at age < 50 of either one:
    - Sudden cardiac death/arrest **OR**
    - Pacemaker or ICD
  - Family history of cardiomyopathy
- Signs and/or symptoms of heart failure, including, but not limited to:
  - Respiratory distress
  - Poor peripheral pulses
  - Feeding difficulty
  - Decreased urine output
  - Edema
  - Hepatomegaly
- Abnormal physical findings, including any one of the following:
  - Clicks, snaps, or gallops
  - Fixed and/or abnormally split S2
  - Decreased pulses
  - Central cyanosis
- Arrhythmia, if one of the following:
  - Supraventricular tachycardia
  - Ventricular tachycardia
- Murmur
  - Pathologic sounding or harsh murmur, diastolic murmur, holosystolic or continuous murmur, late systolic murmur, grade 3/6 systolic murmur or louder, or murmurs that are provoked and become louder with changes in position
  - Presumptively innocent murmur, but in the presence of signs, symptoms, or findings of cardiovascular disease
- Abnormal basic data, including any one of the following:
  - Abnormal ECG
  - Abnormal cardiac biomarkers
  - Desaturation on pulse oximetry
  - Abnormal chest x-ray
- Sickle cell
  - One time screening for risk stratification for pulmonary hypertension in children ≥ 8 years of age<sup>55</sup>
- ~~Suspected pulmonary hypertension~~
- ~~Signs and symptoms of endocarditis~~

- ~~Thromboembolic events~~
  - ~~Patients on anticoagulants, when required to evaluate for thrombus~~
  - ~~Thromboembolic events or stroke<sup>7</sup>~~
- ~~Systemic hematologic diseases that are associated with cardiac findings~~
  - ~~Sickle cell disease and other hemoglobinopathies~~
  - ~~HIV infection~~
  - ~~Chemotherapy or radiation therapy, any one of the following:~~
    - ~~Cardiotoxic chemotherapy, before and following exposure~~
    - ~~Radiation therapy to chest, before and long-term follow-up<sup>12</sup>~~
- Suspicion of Structural Disease, including any one of the following:
  - Premature birth where there is suspicion of a Patent Ductus Arteriosus
  - Vascular Ring, based upon either one:
    - Difficulty breathing with stridor and eating solid foods that might suggest a vascular ring
    - Abnormal barium swallow or bronchoscopy suggesting a vascular ring
- Genetic & Syndrome Related, including any one of the following:
  - Genotype positive for cardiomyopathy, family history of hypertrophic cardiomyopathy or heritable pulmonary arterial hypertension
  - Patient with a known syndrome associated with congenital or acquired heart disease (Down's syndrome, Noonan's syndrome, DiGeorge syndrome, William's syndrome, Trisomy Thirteen, Trisomy Eighteen, Alagille syndrome, chromosomal abnormality associated with cardiovascular disease)
  - Abnormalities of visceral or cardiac situs
  - Known or suspected connective tissue diseases that are associated with congenital or acquired heart disease. (e.g., Marfan's, Loeys-Dietz)
  - ~~Known or suspected muscular dystrophies associated with congenital heart disease~~
  - ~~Mitochondrial or metabolic storage disease (e.g., Fabry's disease)~~
  - Patients with a first-degree relative with a genetic abnormality, such as cardiomyopathies (hypertrophic, dilated, arrhythmogenic right ventricular dysplasia, restrictive, left ventricular noncompaction).
- Maternal-Fetal related, including any one of the following:
  - Maternal infection during pregnancy or delivery with potential fetal/neonatal cardiac [sequelae](#)
  - Maternal phenylketonuria
  - Suspected cardiovascular abnormality on fetal echocardiogram

## ADULT AND PEDIATRIC CONGENITAL HEART DISEASE FOLLOW-UP<sup>16</sup> ‡\*

[‡All surgical or catheter-based repairs allow evaluation PRIOR to the procedure and POSTPROCEDURAL evaluation (within 30 days)]

- For all lesions, TTE is indicated for change in clinical status and/or development of new signs or symptoms
- Infant with any degree of unrepaired **valvular** AS/AR may have surveillance TTE every 1 – 4 weeks as needed
- Surveillance interval for patients with subvalvular stenosis **plus** aortic regurgitation will be dictated by the magnitude of the more significant abnormality (e.g., mild stenosis with moderate regurgitation would have surveillance interval as though stenosis were also moderate).
- Infant with any degree of unrepaired MS may have surveillance TTE every 1 – 4 weeks as needed
- After any surgical or catheter-based repair, evaluation (3-12 months) for a patient with heart failure symptoms
- Annual surveillance in a child with normal prosthetic mitral valve function and no LV dysfunction
- Surveillance (3-12 months) in a child with prosthetic mitral valve and ventricular dysfunction and/or arrhythmia
- Annual surveillance for incomplete or palliative repair (including but not limited to Glenn shunt, Fontan procedure and RV-PA conduit)
- TTE may be unnecessary in a year when cardiac MRI is performed unless clinical indication warrants otherwise

[\*Note: See tables below for specific surveillance intervals.]

**Infancy is defined as between birth and 1 year of age; childhood from 1-11 years of age; and adolescence from 11 to 21 years of age<sup>56</sup>**

~~Where a specific clinical indication is not directly addressed in this guideline, medical necessity determination will be made based on widely accepted standard of care criteria. These criteria are supported by evidence-based or peer-reviewed sources such as medical literature, societal guidelines, and state/national recommendations.~~

**Table 1: Unrepaired Lesion Follow-Up<sup>‡</sup>**

**<sup>‡</sup>Blue shading indicates lifetime surveillance interval**

Unrepaired Lesion	Surveillance Intervals				
	1-3 months	3-6 months	6-12 months	1-2 years	3-5 years
Aortic Stenosis (AS) and/or aortic regurgitation (AR)			Child Asymptomatic ≥ moderate AS/AR	Child Asymptomatic mild AS/AR	



(See <a href="#">section above</a> for surveillance intervals for infants)					
<b>Bicuspid aortic valve with ≤ mild AS/AR and no aortic dilation in a child</b>					<b>3 Years</b>
<b>Atrial septal defect</b>				<b>Moderate size (6-12mm)</b>	<b>Small size (3-6mm)</b>
<b>Double outlet right ventricular (DORV): with balanced systemic and pulmonary circulation</b>	Infant	Child			
<b>Mitral regurgitation (MR)</b>	Infant with ≥ moderate MR		Infant with mild MR. Child with ≥ moderate MR.		Child with mild MR (2-5 years)
<b>Mitral Stenosis (MS)</b> (See <a href="#">section above</a> for surveillance intervals for infants)		Child with ≥ moderate MS		Child with mild MS	
<b>Congenitally corrected transposition of the Great Arteries (ccTGA)</b>		Infant	<b>Moderate or greater A-V valve regurgitation</b>	<b>&lt; Moderate A-V valve regurgitation</b>	
<b>Tricuspid regurgitation (TR)</b>		Infant with ≥ moderate TR	Child with ≥ moderate TR	Child with mild TR	
<b>Unrepaired Lesion</b>	<b>Surveillance Intervals</b>				
	<b>1-3 months</b>	<b>3-6 months</b>	<b>6-12 months</b>	<b>1-2 years</b>	<b>3-5 years</b>
<b>Patent Ductus Arteriosus</b>		Infant		Child	<b>Adult</b>
<b>Pulmonary stenosis (PS)</b>		Infant		Child	
				<b>Adult</b>	

Coarctation		Infant		Child	
				Adult	
Ventricular septal defect (VSD)	Infant with $\geq$ moderate VSD			Child with non-muscular VSD	Child with small muscular VSD
					Adult with any VSD
Anomalous coronary arteries				Moderate to large coronary fistula	Small coronary fistula or RCA arising from left coronary sinus (2-5 years)
<u>Subvalvular AS</u> <small>See section above for information on surveillance intervals for stenosis <b>plus</b> regurgitation</small>	<u>Infant with any degree of stenosis</u>		<u>Child with <math>\geq</math> moderate stenosis</u>	<u>Child with mild stenosis</u>	
			Adult with $\geq$ moderate stenosis	Adult with mild stenosis	
<u>Supravalvular AS</u>		<u>Infant with any degree of stenosis</u>	<u>Child with <math>\geq</math> moderate stenosis</u>	<u>Child with mild stenosis</u>	2-5 years Adult with $\geq$ moderate stenosis
			Adult with $\geq$ moderate stenosis	Adult with mild stenosis	
<u>Total anomalous pulmonary venous connection (TAPVC)</u>	<u>Prior to planned repair or for change in clinical status and/or development of new signs and symptoms</u>				

**Note:** Despite surgical or catheter-based procedures, most patients with congenital heart disease are left with disorders or **sequelae** that are known consequences of the reparative intervention. These disorders can include arrhythmias, valvular and myocardial dysfunction, and vascular and non-cardiovascular abnormalities. These sequelae can be categorized as mild, moderate, or severe. Use clinical judgement to assess the nature of the sequelae when adjudicating cases based on the follow-up criteria below.

**Table 2: Postprocedural Follow-up<sup>†</sup>**

<sup>†</sup>Blue shading indicates lifetime surveillance interval

Post-procedure: Surgical or Catheter- Based	Surveillance Intervals				
	1-3 months	3-6 months	6-12 months	1-2 years	3-5 years
Post-procedural treatment of AS or AR with repair or replacement	Infant with $\geq$ moderate AS or AR or LV dysfunction	Infant with $\leq$ mild AS or AR and no LV dysfunction	Child with $\geq$ moderate AS or AR	Child with $\leq$ mild AS or AR	
ASD device closure: no or mild sequelae	Within 1 <sup>st</sup> year	Within 1 <sup>st</sup> year	At 1 year		2-5 years
ASD surgical repair: no or mild sequelae			Within 1 <sup>st</sup> year		2-5 years
ASD: device closure or surgical repair with residual shunt, valvular or ventricular dysfunction, arrhythmias, or pulmonary hypertension		3-12 months			
DORV: no or mild sequelae			Within 1 <sup>st</sup> year	1-2 Years	
DORV: valvular or ventricular		3-12 months			

dysfunction, outflow obstruction, arrhythmias, branch pulmonary artery stenosis, presence of RV-PA conduit				
--	--	--	--	--

Post-procedure: Surgical or Catheter- Based	Surveillance Intervals				
	1-3 months	3-6 months	6-12 months	1-2 years	3-5 years
Tricuspid valve surgery or catheter-based procedure: no or mild sequelae				1-2 years	
Tricuspid valve surgery or catheter-based procedure: valvular or ventricular dysfunction or arrhythmias			Child	Adult	
Pulmonary Stenosis: no or mild sequelae			Child with moderate or severe sequelae	Child with no or mild sequelae	Adult
Coarctation: no or mild sequelae		Within 1 <sup>st</sup> year		After 1 <sup>st</sup> year	
PDA: no or mild sequelae				Annually within 1 <sup>st</sup> two years	Five years after 1 <sup>st</sup> two years*
PDA: post-procedural left PA stenosis				1-2 years	

or aortic obstruction					
Tetralogy of Fallot (ToF): after transcatheter pulmonary valve replacement, with no or mild sequelae	1 month	6 months		Annually	
Post-Procedure: Surgical or Catheter-Based	Surveillance Intervals				
	1-3 months	3-6 months	6-12 months	1-2 years	3-5 years
ToF: patient with conduit dysfunction valvular or ventricular dysfunction, pulmonary artery stenosis, or arrhythmias			6-12 months		
Congenitally corrected transposition on the Great Arteries (ccTGA): no or mild sequelae		Within 1 <sup>st</sup> year		1-2 years	
ccTGA: valvular or ventricular dysfunction, outflow obstruction, ventricular - PA conduit		3-12 months			
d-TGA: no or mild sequelae	Infant with moderate sequelae	Within 1 <sup>st</sup> year		1-2 years	
d-TGA: moderate or		3-12 months			

greater valvular or ventricular dysfunction, outflow obstruction, branch pulmonary artery stenosis or arrhythmias, presence of RV-PA conduit					
Post-Procedure: Surgical or Catheter-Based	Surveillance Intervals				
	1-3 months	3-6 months	6-12 months	1-2 years	3-5 years
d-TGA: dilated neo-aortic root and increasing Z-Score or neo-aortic regurgitation				1-2 years	
Truncus Arteriosus (TA): no or mild sequelae	Within 1 <sup>st</sup> year		After 1 <sup>st</sup> year		
TA: moderate or greater truncal stenosis / regurgitation		3-6 months			
TA: Residual VSD, RV-PA conduit, branch pulmonary artery obstruction		3-12 months			
VSD: no or mild sequelae or			Within 1 <sup>st</sup> year		2-3 years

small residual shunt					
VSD: significant residual shunt, valvular or ventricular dysfunction, arrhythmias, or pulmonary hypertension		3-12 months			
Post-procedure: Surgical or Catheter-Based	Surveillance Intervals				
	1-3 months	3-6 months	6-12 months	1-2 years	3-5 years
Anomalous coronary arteries	Within 1 <sup>st</sup> year	Infant with or without ventricular or valvular dysfunction  Child or adult with ventricular or valvular dysfunction		Annually	
<u>Subvalvular AS</u> <small>See section above for information on surveillance intervals plus regurgitation</small>	<u>Infant with ≥ moderate stenosis</u>	<u>Infant with ≤ mild stenosis</u>		<u>Child with ≤ mild stenosis and/or AR</u>	
				<u>Adult with ≤ mild stenosis and/or AR</u>	
<u>Subvalvular AS</u> <i>continued</i>		<u>3-12 months</u> <u>Child ≥ moderate stenosis</u>			
		<u>3-12 months</u> <u>Adult ≥ moderate stenosis</u>			
<u>Supravalvular AS</u>			<u>Patient with ≥ moderate stenosis</u>		<u>2-5 years</u> <u>Patient with ≤ mild stenosis</u>

<u>Total anomalous pulmonary venous connection</u>		<u>Infant with mild or no sequelae</u>		<u>Child with mild or no sequelae</u>	<u>Adult with mild or no sequelae</u>
--	--	--	--	---	---

**\*PDA lifetime surveillance applies only to device closure; PDA lifetime surveillance is not indicated for surgical closure.**

## BACKGROUND

Transthoracic echocardiography (TTE) uses ultrasound to image the structures of the heart in a real time format, providing 2-dimensional, cross-sectional images. The addition of Doppler ultrasound derives hemodynamic data from flow velocity versus time measurements, as well as from color-coded two-dimensional representations of flow velocities.

TTE’s safety and versatility in examining cardiac structure, function, and hemodynamics lends to its utility for numerous indications in children and adults.

TEE (transesophageal echocardiography) widens the scope of utility for echocardiographic imaging, and its indications are covered in a separate guideline.





## Abbreviations:

AS	Aortic stenosis
AR	Aortic regurgitation
ASD	Atrial septal defect
BNP	B-type natriuretic peptide or brain natriuretic peptide
CABG	Coronary artery bypass grafting surgery
CAD	Coronary artery disease
ccTGA	Congenitally corrected transposition of the Great Arteries
CMR	Cardiovascular magnetic resonance
CRT	Cardiac resynchronization therapy
CT	Computed tomography
CVA	Cerebrovascular accident
DORV	Double outlet right ventricle
d-TGA	D-Transposition of the Great Arteries
ECG	Electrocardiogram
EF	Ejection fraction
HCM	Hypertrophic cardiomyopathy
HTN	Hypertension
HF	Heart failure
ICD	Implantable cardioverter-defibrillator
LAA	Left atrial appendage
LV	Left ventricular/ventricle
LVEF	Left ventricular ejection fraction
LVH	Left ventricular hypertrophy
MI	Myocardial infarction
MR	Mitral regurgitation
MS	Mitral stenosis
PA	Pulmonary artery
<u>PAC</u>	<u>Premature atrial complex</u>
PDA	Patent ductus arteriosus
PFO	Patent foramen ovale
PS	Pulmonary stenosis
PVC	Premature ventricular contraction
RV	Right ventricular/ventricle
TA	Truncus arteriosus
TAVR	Transcatheter aortic valve replacement
TEE	Transesophageal echocardiogram
TIA	Transient ischemic attack
ToF	Tetralogy of Fallot
TR	Tricuspid regurgitation
TTE	Transthoracic echocardiogram
VAD	Ventricular assist device

VF Ventricular fibrillation  
VSD Ventricular septal defect  
VT Ventricular tachycardia

## POLICY HISTORY

Date	Summary
<u>2023</u>	<ul style="list-style-type: none"> <li><del>Clarified syncope indications</del></li> <li><del>Pulmonary hypertension: added section for annual screening in certain diseases, added indication for repeat following pulmonary embolism evaluate for chronic thromboembolic pulmonary hypertension</del></li> <li><del>Cardiomyopathy: added examples of infiltrative processes, added intervals for repeat testing in different forms of amyloidosis</del></li> <li><del>Added indication for surveillance following radiation therapy</del></li> <li><del>Hypertrophic cardiomyopathy: added statement on imaging related to Camzyos therapy</del></li> <li><del>Clarified surveillance related to exposure to cardiotoxic medication</del></li> <li><del>Added section on COVID</del></li> <li><del>Added section on inflammatory and autoimmune diseases</del></li> <li><del>Added section on neuromuscular disorders</del></li> <li><del>Reorganized Pediatric section for clarity</del></li> <li><del>Added sections on supravalvular and subvalvular AS and total anomalous pulmonary venous connection to congenital heart disease table</del></li> <li>Added statement on clinical indications not addressed in this guideline</li> </ul>
<del>June 2022</del>	<ul style="list-style-type: none"> <li><del>Within the Hypertrophic Cardiomyopathy section, added To guide therapy</del></li> </ul>
<del>February 2022</del>	<ul style="list-style-type: none"> <li><del>Modified definition of pathological Q waves</del></li> <li><del>Added indications for murmur evaluation</del></li> <li><del>Clarified definition of frequent PVC</del></li> <li><del>Added annual surveillance TTE following palliative procedures in congenital heart disease.</del></li> <li><del>Added post op atrial switch for d TGA surveillance intervals (table)</del></li> <li><del>Screening for PH in sickle cell added</del></li> <li><del>Revised surveillance indications post op prosthetic valve and native valve repair</del></li> </ul>

	<ul style="list-style-type: none"> <li>● Expanded guidelines for AS/AR, MS/MR, TR, PS, ASD, TOF, DORV, TGA, TA, and coronary anomalies</li> <li>● Reorganized pediatric indications for clarity</li> <li>● Added section for pediatric hypertension (both initial evaluation and follow-up)</li> </ul>
March 2021	<ul style="list-style-type: none"> <li>● Added the following to prosthetic heart valves: <ul style="list-style-type: none"> <li>○ Routine surveillance of surgical bioprosthetic valve: 5 and 10 years after surgery and then annually</li> <li>○ Routine surveillance of surgical mitral valve repair: 1 year and then every 2-3 years</li> </ul> </li> <li>● Added section on heart failure with recovered EF under cardiomyopathy <ul style="list-style-type: none"> <li>○ Heart failure with recovered left ventricular ejection fraction defined as: <ul style="list-style-type: none"> <li>■ 1) Documentation of a decreased LVEF &lt;40% at baseline; AND</li> <li>■ 2) ≥10% absolute improvement in LVEF; AND</li> <li>■ 3) second measurement of LVEF &gt;40% (Wilcox, 2020) <ul style="list-style-type: none"> <li>○ Repeat echocardiogram every 6 months until 12-18 months of heart failure with a recovered EF, then then annually for 2 years, then every 3-5 years</li> <li>○ Higher risk patient (persistent left bundle branch block, genetic cardiomyopathy, higher biomarker profiles) may have annual follow up</li> </ul> </li> </ul> </li> </ul> </li> <li>● Created a separate section on hypertrophic cardiomyopathy (HCM) with the following additions: <ul style="list-style-type: none"> <li>○ Evaluation of patients with HCM who have undergone septal reduction therapy within 3-6 months after the procedure</li> <li>○ Screening for patients who are clinically unaffected (genotype positive and phenotype negative): <ul style="list-style-type: none"> <li>■ Children every 1-2 years</li> <li>■ Adults every 3-5 years</li> </ul> </li> <li>○ Screening of first degree relatives is recommended at the time HCM is diagnosed in the family member and serial follow-up as below: <ul style="list-style-type: none"> <li>■ Children from genotype positive families and families with early onset disease every 1-2 years</li> <li>■ All other children every 2-3 years</li> </ul> </li> </ul> </li> </ul>

	<ul style="list-style-type: none"> <li>• <del>Adults every 3-5 years</del></li> <li>• <del>Additional information added under follow-up with Kawasaki's disease</del> <ul style="list-style-type: none"> <li>○ <del>For patients with important and evolving coronary artery abnormalities during the acute illness, echocardiograms may need to be more frequent. In the setting of increasing size of coronary aneurysms, echocardiogram can be performed up to twice per week until dimensions have stopped progressing, then at least once per week in the first 45 days of illness, and then monthly until the third month after onset.</del></li> </ul> </li> </ul>
August 2020	<ul style="list-style-type: none"> <li>• <del>For prosthetic valve with TTE specified routine surveillance as <math>\geq</math> 3 yrs. (after valve implantation) of prosthetic valve or native valve repair</del></li> <li>• <del>Valvular dysfunction defined as including but not limited to:</del> <ul style="list-style-type: none"> <li>○ <del>Chest pain</del></li> <li>○ <del>Shortness of breath</del></li> <li>○ <del>New or increased murmur on heart examination</del></li> </ul> </li> <li>• <del>Clarified syncope can be either known or suspected</del></li> <li>• <del>Further definition of ECG evidence of prior MI (pathologic Q waves) defined as below:</del> <ul style="list-style-type: none"> <li>○ <del>&gt; 40 ms (1 mm) wide</del></li> <li>○ <del>&gt; 2 mm deep</del></li> <li>○ <del>&gt; 25% of depth of QRS complex</del></li> </ul> </li> <li>• <del>Added 12 months to the following statement: Follow up of aortic disease when there has been no surgical intervention:</del> <ul style="list-style-type: none"> <li>○ <del>Acute dissection: 1 month, 6 months, 12 months, then annually</del></li> <li>○ <del>Chronic dissection: annually</del></li> </ul> </li> <li>• <del>For heart failure removed the requirement for a clear precipitating change in medication or diet.</del></li> <li>• <del>Further defined signs/symptoms suggestive of VAD-related complications as including but not limited to:</del> <ul style="list-style-type: none"> <li>○ <del>TIA or stroke</del></li> <li>○ <del>Infection</del></li> <li>○ <del>Murmur suggestive of aortic insufficiency</del></li> <li>○ <del>Worsening heart failure</del></li> </ul> </li> <li>• <del>Known adult congenital heart disease with a change in clinical status or cardiac exam including but not limited to:</del> <ul style="list-style-type: none"> <li>○ <del>Chest Pain</del></li> <li>○ <del>Shortness of breath</del></li> </ul> </li> </ul>

	<ul style="list-style-type: none"> <li>○ <del>New or increased murmur on physical exam</del></li> </ul>
March 2020	<ul style="list-style-type: none"> <li>● <del>Added general information section as Introduction which outlines requirements for documentation of pertinent office notes by a licensed clinician, and inclusion of laboratory testing and relevant imaging results for case review.</del></li> <li>● <del>Added clarification of abnormal EKG to include evidence of prior myocardial infarction, including pathologic Q waves</del></li> <li>● <del>Added clarification of indication for frequent PVCs to include greater than 30 per hour on remote monitoring</del></li> <li>● <del>Added clarification that annual evaluation of bioprosthetic heart valves older than 10 years, to replace prosthetic heart valves</del></li> <li>● <del>Added statement about routine surveillance of PFO not indicated</del></li> <li>● <del>Separated sections on pericardial disease and cardiac source of emboli/ cardiac mass</del></li> <li>● <del>Added clarification cardiac source of emboli to include the following: Embolic source in patients with recent transient ischemic attack (TIA), stroke, or peripheral vascular emboli</del></li> <li>● <del>Added clarification of cardiac mass to include the following: evaluation of mass and re-evaluation when findings would alter therapy</del></li> <li>● <del>Added clarification of hypertensive heart disease to include asymptomatic left ventricular hypertrophy, cardiomegaly, or evidence of clinical heart failure</del></li> <li>● <del>Added indication for suspected cardiac amyloid to monitor disease progression and/or response to therapy, and to guide initiation and management of anticoagulation (TEE may be preferred)</del></li> <li>● <del>Added clarification of imaging for surveillance for cardiotoxic chemotherapy to include the following: TTE is the method of choice for the evaluation of patients prior to cardiotoxic chemotherapy, and subsequently for monitoring and follow up. The frequency of testing should be left to the discretion of the ordering physician, but generally no more often than at baseline and every 6 weeks thereafter.</del></li> <li>● <del>Added separate section on indications for TTE during pregnancy to include the following:</del></li> </ul>

- ~~Valvular stenosis: mild can evaluate each trimester and prior to deliver; moderate to severe can evaluate monthly~~
- ~~Valvular regurgitation: mild moderate can evaluate each trimester and prior to delivery; severe regurgitation can evaluate monthly~~
- ~~Pre-pregnancy evaluation with mechanical or bioprosthetic heart valves if not done within the previous year~~
- ~~Prior postpartum cardiomyopathy: can repeat at the end of the 1<sup>st</sup> and 2<sup>nd</sup> trimesters, 1 month prior to delivery, after delivery prior to hospital discharge, 1 month postpartum, and serially including up to 6 months after normalization of ejection fraction~~
- ~~Syndromes potentially involving the aorta (i.e, Marfan's, Ehlers-Danlos, Loeys-Dietz, or Turner syndrome): for mildly dilated aorta can repeat TTE every 12 weeks; for severely dilated aorta can repeat TTE monthly. Continued evaluation allowable for 6 months postpartum~~
- ~~Extensive update to adult and pediatric congenital heart disease sections to include the following:~~
  - ~~Evaluation prior to surgical or catheter-based procedure and postprocedural evaluation (within 30 days)~~
  - ~~Evaluation after any surgical or catheter-based repair (3-12 months) for a patient with heart failure symptoms~~
  - ~~Complete chart added to include timing of TTE follow-up in infants, children, and adults based on the lesion present and whether the lesion was unrepaired or surgical or catheter-based repair had been performed~~
  - ~~Added separate section on follow-up of patients with double-outlet right ventricle, transposition of the great arteries, and truncus arteriosus~~
- ~~Removed chart and background information regarding physiologic stages of adult CHD~~
- ~~Added separate section for coronary anomalies to include the following:~~
  - ~~Routine surveillance (2-5 years) in an asymptomatic patient with anomalous right coronary artery from the left aortic sinus~~

	<ul style="list-style-type: none"> <li>○ <del>Routine surveillance (2-5 years) in an asymptomatic patient with small coronary fistula and 1-2 years for moderate or larger coronary fistula</del></li> <li>● <del>Updates to TTE in pediatric patients include the following:</del> <ul style="list-style-type: none"> <li>○ <del>Clarification of congenital heart disease with a change in clinical status with the addition of “or to guide therapy”</del></li> <li>○ <del>Added annual surveillance in a child with normal prosthetic mitral valve function and no LV dysfunction</del></li> <li>○ <del>Added surveillance (3-12 months) in a child with prosthetic mitral valve and ventricular dysfunction and/or arrhythmias</del></li> </ul> </li> <li>● <del>Updated and added new references</del></li> </ul>
November 2019	<ul style="list-style-type: none"> <li>● <del>Added CPT code +93356</del></li> </ul>
July 2019	<ul style="list-style-type: none"> <li>● <del>Added indication for hypotension of suspected cardiac etiology</del></li> <li>● <del>Removed indication for respiratory failure or hypoxemia of uncertain etiology</del></li> <li>● <del>Clarification of murmur indication with “when there is a reasonable suspicion of valvular heart disease such as high grade, holosystolic, continuous, or diastolic murmur”</del></li> <li>● <del>Clarified frequent PVCs as greater than 30 per hour</del></li> <li>● <del>Added indication for unevaluated left bundle branch block</del></li> <li>● <del>Added indication for exercise induced syncope</del></li> <li>● <del>For perioperative evaluation for solid organ transplantation, added annual study prior to transplantation</del></li> <li>● <del>Removed indication for re-evaluation (&lt;1 yr) in patients with moderate or severe aortic stenosis, who will be subjected to increased hemodynamic demands (e.g. noncardiac surgery, pregnancy)</del></li> <li>● <del>Removed tertiary syphilis or Takayasu’s Arteritis indication</del></li> <li>● <del>Pulmonary hypertension:</del> <ul style="list-style-type: none"> <li>○ <del>Clarified re-evaluation for a change in clinical status or cardiac exam, or to guide therapy (every 6-12 months, or more frequently to guide therapy). Annual indication removed.</del></li> <li>○ <del>Screening for scleroderma added</del></li> </ul> </li> <li>● <del>Removed indications for history of rheumatic heart disease and exposure to medications that could result in valvular heart disease</del></li> </ul>



	<ul style="list-style-type: none"> <li>• <del>Added mild valvular regurgitation as an indication for testing every 3 years</del></li> <li>• <del>Added indication for annual evaluation of prosthetic heart valves older than 10 years</del></li> <li>• <del>In depth indications for HOCM</del></li> <li>• <del>LVAD and transplant indications added</del></li> <li>• <del>Removed chart on specific chemotherapeutic agents</del></li> <li>• <del>Added detailed indications for adult congenital heart disease and serial follow up</del></li> <li>• <del>Removed indications for presyncope for pediatric patients</del></li> <li>• <del>Revised murmur indication in pediatric patients with more criteria for pathologic murmur</del></li> <li>• <del>Added definitions of age groups for pediatric patients (infancy, childhood, and adolescence)</del></li> </ul>
--	--

## REFERENCES

1. Douglas PS, Garcia MJ, Haines DE, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance Endorsed by the American College of Chest Physicians. *J Am Coll Cardiol*. Mar 1 2011;57(9):1126-66. doi:10.1016/j.jacc.2010.11.002
2. Doherty JU, Kort S, Mehran R, Schoenhagen P, Soman P. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2017 Appropriate Use Criteria for Multimodality Imaging in Valvular Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. Sep 26 2017;70(13):1647-1672. doi:10.1016/j.jacc.2017.07.732
3. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. Aug 1 2017;70(5):e39-e110. doi:10.1016/j.jacc.2017.03.003
4. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. *J Am Coll Cardiol*. Dec 9 2014;64(22):e77-137. doi:10.1016/j.jacc.2014.07.944
5. Lentine KL, Costa SP, Weir MR, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. *J Am Coll Cardiol*. Jul 31 2012;60(5):434-80. doi:10.1016/j.jacc.2012.05.008
6. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J*. Jan 1 2016;37(1):67-119. doi:10.1093/eurheartj/ehv317
7. Saric M, Armour AC, Arnaout MS, et al. Guidelines for the Use of Echocardiography in the Evaluation of a Cardiac Source of Embolism. *J Am Soc Echocardiogr*. Jan 2016;29(1):1-42. doi:10.1016/j.echo.2015.09.011

8. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). *European Heart Journal*. 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237
9. Klings ES, Machado RF, Barst RJ, et al. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. *Am J Respir Crit Care Med*. Mar 15 2014;189(6):727-40. doi:10.1164/rccm.201401-0065ST
10. Doherty JU, Kort S, Mehran R, Schoenhagen P, Soman P. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac Structure and Function in Nonvalvular Heart Disease : A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and the Society of Thoracic Surgeons. *J Nucl Cardiol*. Aug 2019;26(4):1392-1413. doi:10.1007/s12350-019-01751-7
11. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. Jun 10 2014;63(22):e57-185. doi:10.1016/j.jacc.2014.02.536
12. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. Feb 2 2021;77(4):e25-e197. doi:10.1016/j.jacc.2020.11.018
13. Bonow RO, O'Gara PT, Adams DH, et al. 2020 Focused Update of the 2017 ACC Expert Consensus Decision Pathway on the Management of Mitral Regurgitation: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. May 5 2020;75(17):2236-2270. doi:10.1016/j.jacc.2020.02.005
14. Lancellotti P, Tribouilloy C, Hagendorff A, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. Jul 2013;14(7):611-44. doi:10.1093/ehjci/jet105
15. Otto CM, Kumbhani DJ, Alexander KP, et al. 2017 ACC Expert Consensus Decision Pathway for Transcatheter Aortic Valve Replacement in the Management of Adults With Aortic Stenosis: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol*. Mar 14 2017;69(10):1313-1346. doi:10.1016/j.jacc.2016.12.006
16. Sachdeva R, Valente AM, Armstrong AK, et al. ACC/AHA/ASE/HRS/ISACHD/SCAI/SCCT/SCMR/SOPE 2020 Appropriate Use Criteria for Multimodality Imaging During the Follow-Up Care of Patients With Congenital Heart Disease: A

- Report of the American College of Cardiology Solution Set Oversight Committee and Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Pediatric Echocardiography. *J Am Coll Cardiol*. Feb 18 2020;75(6):657-703. doi:10.1016/j.jacc.2019.10.002
17. Chiabrando JG, Bonaventura A, Vecchié A, et al. Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review. *J Am Coll Cardiol*. Jan 7 2020;75(1):76-92. doi:10.1016/j.jacc.2019.11.021
  18. Klein AL, Abbata S, Agler DA, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. *J Am Soc Echocardiogr*. Sep 2013;26(9):965-1012.e15. doi:10.1016/j.echo.2013.06.023
  19. Ohte N, Ishizu T, Izumi C, et al. JCS 2021 Guideline on the Clinical Application of Echocardiography. *Circ J*. Nov 25 2022;86(12):2045-2119. doi:10.1253/circj.CJ-22-0026
  20. Habib G, Badano L, Tribouilloy C, et al. Recommendations for the practice of echocardiography in infective endocarditis. *Eur J Echocardiogr*. Mar 2010;11(2):202-19. doi:10.1093/ejechocard/jeq004
  21. Bhawe NM, Nienaber CA, Clough RE, Eagle KA. Multimodality Imaging of Thoracic Aortic Diseases in Adults. *JACC Cardiovasc Imaging*. Jun 2018;11(6):902-919. doi:10.1016/j.jcmg.2018.03.009
  22. Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). *Eur Heart J*. Nov 1 2014;35(41):2873-926. doi:10.1093/eurheartj/ehu281
  23. Hiratzka LF, Creager MA, Isselbacher EM, et al. Surgery for Aortic Dilatation in Patients With Bicuspid Aortic Valves: A Statement of Clarification From the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. Feb 16 2016;67(6):724-731. doi:10.1016/j.jacc.2015.11.006
  24. Svensson LG, Adams DH, Bonow RO, et al. Aortic valve and ascending aorta guidelines for management and quality measures. *Ann Thorac Surg*. Jun 2013;95(6 Suppl):S1-66. doi:10.1016/j.athoracsur.2013.01.083
  25. Terdjman M, Bourdarias JP, Farcot JC, et al. Aneurysms of sinus of Valsalva: two-dimensional echocardiographic diagnosis and recognition of rupture into the right heart cavities. *J Am Coll Cardiol*. May 1984;3(5):1227-35. doi:10.1016/s0735-1097(84)80181-3
  26. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American

Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. *J Am Coll Cardiol*. Apr 6 2010;55(14):e27-e129.

doi:10.1016/j.jacc.2010.02.015

27. Isselbacher EM, Preventza O, Black JH, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;146(24):e334-e482. doi:10.1161/CIR.0000000000001106

28. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. *Pediatrics*. Sep 2017;140(3)doi:10.1542/peds.2017-1904

29. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. Apr 2016;29(4):277-314. doi:10.1016/j.echo.2016.01.011

30. Patel MR, White RD, Abbara S, et al. 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: a joint report of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Foundation Appropriate Use Criteria Task Force. *J Am Coll Cardiol*. May 28 2013;61(21):2207-31. doi:10.1016/j.jacc.2013.02.005

31. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. Oct 15 2013;62(16):e147-239. doi:10.1016/j.jacc.2013.05.019

32. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. *Eur Heart J*. Sep 7 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340

33. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. Dec 22 2020;76(25):e159-e240. doi:10.1016/j.jacc.2020.08.045

34. Maddox TM, Januzzi JL, Jr., Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. Feb 16 2021;77(6):772-810. doi:10.1016/j.jacc.2020.11.022

35. Wilcox JE, Fang JC, Margulies KB, Mann DL. Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel. *J Am Coll Cardiol*. Aug 11 2020;76(6):719-734. doi:10.1016/j.jacc.2020.05.075

36. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. *Heart Rhythm*. Jul 2014;11(7):1305-23. doi:10.1016/j.hrthm.2014.03.043
37. Administration USFaD. FDA approves new drug to improve heart function in adults with rare heart condition. Accessed February, 2023.  
[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/214998s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214998s000lbl.pdf)
38. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. Sep 2014;27(9):911-39. doi:10.1016/j.echo.2014.07.012
39. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur Heart J*. Sep 21 2016;37(36):2768-2801. doi:10.1093/eurheartj/ehw211
40. Baldassarre LA, Ganatra S, Lopez-Mattei J, et al. Advances in Multimodality Imaging in Cardio-Oncology: JACC State-of-the-Art Review. *J Am Coll Cardiol*. Oct 18 2022;80(16):1560-1578. doi:10.1016/j.jacc.2022.08.743
41. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Heart Rhythm*. Oct 2018;15(10):e73-e189. doi:10.1016/j.hrthm.2017.10.036
42. Stainback RF, Estep JD, Agler DA, et al. Echocardiography in the Management of Patients with Left Ventricular Assist Devices: Recommendations from the American Society of Echocardiography. *J Am Soc Echocardiogr*. Aug 2015;28(8):853-909. doi:10.1016/j.echo.2015.05.008
43. Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) Guidelines for the Care of Heart Transplant Recipients. *The Journal of Heart and Lung Transplantation*. doi:10.1016/j.healun.2022.09.023
44. Davis MB, Arany Z, McNamara DM, Goland S, Elkayam U. Peripartum Cardiomyopathy: JACC State-of-the-Art Review. *J Am Coll Cardiol*. Jan 21 2020;75(2):207-221. doi:10.1016/j.jacc.2019.11.014
45. Stout KK, Daniels CJ, Aboulhosen JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. Apr 2 2019;139(14):e637-e697. doi:10.1161/cir.0000000000000602
46. Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). *Circulation*. Dec 2 2008;118(23):e714-833. doi:10.1161/circulationaha.108.190690



47. Gewitz MH, Baltimore RS, Tani LY, et al. Revision of the Jones Criteria for the Diagnosis of Acute Rheumatic Fever in the Era of Doppler Echocardiography. *Circulation*. 2015;131(20):1806-1818. doi:10.1161/CIR.0000000000000205
48. Miner JJ, Kim AH. Cardiac manifestations of systemic lupus erythematosus. *Rheum Dis Clin North Am*. Feb 2014;40(1):51-60. doi:10.1016/j.rdc.2013.10.003
49. Nishigami K. Role of cardiovascular echo in patients with Takayasu arteritis. *J Echocardiogr*. Dec 2014;12(4):138-41. doi:10.1007/s12574-014-0232-2
50. Alsaied T, Tremoulet AH, Burns JC, et al. Review of Cardiac Involvement in Multisystem Inflammatory Syndrome in Children. *Circulation*. 2021;143(1):78-88. doi:10.1161/CIRCULATIONAHA.120.049836
51. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. *Circulation*. Apr 25 2017;135(17):e927-e999. doi:10.1161/cir.0000000000000484
52. Gluckman TJ, Bhavne NM, Allen LA, et al. 2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. May 3 2022;79(17):1717-1756. doi:10.1016/j.jacc.2022.02.003
53. Feingold B, Mahle WT, Auerbach S, et al. Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. *Circulation*. Sep 26 2017;136(13):e200-e231. doi:10.1161/cir.0000000000000526
54. Campbell RM, Douglas PS, Eidem BW, Lai WW, Lopez L, Sachdeva R. ACC/AAP/AHA/ASE/HRS/SCAI/SCCT/SCMR/SOPE 2014 appropriate use criteria for initial transthoracic echocardiography in outpatient pediatric cardiology: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Academy of Pediatrics, American Heart Association, American Society of Echocardiography, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Pediatric Echocardiography. *J Am Coll Cardiol*. Nov 11 2014;64(19):2039-60. doi:10.1016/j.jacc.2014.08.003
55. Benza RL. Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment. *Lung*. Jul-Aug 2008;186(4):247-254. doi:10.1007/s00408-008-9092-8
56. Hagan JF, Shaw JS, Duncan PM. Bright Futures: Guidelines for Health Supervision of Infants, Children and Adolescents. American Academy of Pediatrics. Updated 2017. Accessed January 27, 2023. [https://brightfutures.aap.org/Bright%20Futures%20Documents/BF4\\_Introduction.pdf](https://brightfutures.aap.org/Bright%20Futures%20Documents/BF4_Introduction.pdf)

## POLICY HISTORY

<p><u>Date</u> <u>April 2023</u></p>	<p><u>Summary</u></p> <ul style="list-style-type: none"> <li>• <u>Expanded and clarified indications based upon ECG abnormalities</u></li> <li>• <u>Clarified arrhythmias (premature atrial complexes (PAC)) which do not meet criteria for approval.</u></li> <li>• <u>Expanded and clarified surveillance imaging criteria for thoracic aortic aneurysm in Turner's syndrome</u></li> <li>• <u>Added Takotsubo cardiomyopathy to section on surveillance for cardiomyopathy with recovered left ventricular ejection fraction</u></li> <li>• <u>Expanded indication for screening in suspected cardiac sarcoidosis</u></li> <li>• <u>Expanded section on post heart transplant surveillance</u></li> <li>• <u>Added screening in children with sickle cell disease</u></li> <li>• <u>Expanded section on aortopathic syndromes, cardiovascular disease in pregnancy</u></li> <li>• <u>Clarified syncope indications</u></li> <li>• <u>Pulmonary hypertension: added section for annual screening in certain diseases, added indication for repeat following pulmonary embolism evaluate for chronic thromboembolic pulmonary hypertension</u></li> <li>• <u>Cardiomyopathy: added examples of infiltrative processes, added intervals for repeat testing in different forms of amyloidosis</u></li> <li>• <u>Added indication for surveillance following radiation therapy</u></li> <li>• <u>Hypertrophic cardiomyopathy: added statement on imaging related to Camzyos therapy</u></li> <li>• <u>Clarified surveillance related to exposure to cardiotoxic medication</u></li> <li>• <u>Added section on COVID</u></li> <li>• <u>Added section on inflammatory and autoimmune diseases</u></li> <li>• <u>Added section on neuromuscular disorders</u></li> <li>• <u>Reorganized Pediatric section for clarity</u></li> <li>• <u>Added sections on supralvalvular and subvalvular AS and total anomalous pulmonary venous connection to congenital heart disease table</u></li> <li>• <u>Added statement on clinical indications not addressed in this guideline</u></li> </ul>
<p><u>June 2022</u></p>	<ul style="list-style-type: none"> <li>• <u>Within the Hypertrophic Cardiomyopathy section, added To guide therapy</u></li> </ul>
<p><u>February 2022</u></p>	<ul style="list-style-type: none"> <li>• <u>Modified definition of pathological Q waves</u></li> <li>• <u>Added indications for murmur evaluation</u></li> <li>• <u>Clarified definition of frequent PVC</u></li> <li>• <u>Added annual surveillance TTE following palliative procedures in congenital heart disease.</u></li> </ul>



	<ul style="list-style-type: none"> <li>• <u>Added post op atrial switch for d-TGA surveillance intervals (table)</u></li> <li>• <u>Screening for PH in sickle cell added</u></li> <li>• <u>Revised surveillance indications post op prosthetic valve and native valve repair</u></li> <li>• <u>Expanded guidelines for AS/AR, MS/MR, TR, PS, ASD, TOF, DORV, TGA, TA, and coronary anomalies</u></li> <li>• <u>Reorganized pediatric indications for clarity</u></li> <li>• <u>Added section for pediatric hypertension (both initial evaluation and follow-up)</u></li> </ul>
--	--

aorta

## ADDITIONAL RESOURCES

1. Anderson JB, Willis M, Lancaster H, Leonard K, Thomas C. The Evaluation and Management of Pediatric Syncope. *Pediatr Neurol*. Feb 2016;55:6-13. doi:10.1016/j.pediatrneurol.2015.10.018
2. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. *Heart Rhythm*. Jul 2014;11(7):1305-23. doi:10.1016/j.hrthm.2014.03.043
3. Hilfiker-Kleiner D, Haghighi A, Nonhoff J, Bauersachs J. Peripartum cardiomyopathy: current management and future perspectives. *Eur Heart J*. May 7 2015;36(18):1090-7. doi:10.1093/eurheartj/ehv009
4. Pellikka PA, Nagueh SF, Elhendy AA, Kuehl CA, Sawada SG. American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. *J Am Soc Echocardiogr*. Sep 2007;20(9):1021-41. doi:10.1016/j.echo.2007.07.003
5. Porter TR, Shillcutt SK, Adams MS, et al. Guidelines for the use of echocardiography as a monitor for therapeutic intervention in adults: a report from the American Society of Echocardiography. *J Am Soc Echocardiogr*. Jan 2015;28(1):40-56. doi:10.1016/j.echo.2014.09.009
6. Wunderlich NC, Beigel R, Ho SY, et al. Imaging for Mitral Interventions: Methods and Efficacy. *JACC Cardiovasc Imaging*. Jun 2018;11(6):872-901. doi:10.1016/j.jcmg.2018.02.024

**Reviewed / Approved by NIA Clinical Guideline Committee**

**Disclaimer:** Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates (“Magellan”). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

**Disclaimer:** *National Imaging Associates, Inc. (NIA) authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Evolent Health LLC subsidiaries including, but not limited to, National Imaging Associates (“NIA”). The policies constitute only the reimbursement and coverage guidelines of NIA. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. NIA reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.*